BOTTOM LINE
Despite a relatively low dose of 10 mg given once a day, enalapril (Vasotec) was at least as effective as telmisartan (Micardis) and showed a trend toward greater benefit in preventing decline in glomerular filtration rate. Although this study measured a disease-oriented endpoint, its results are consistent with the body of literature that supports the less expensive angiotensin-converting enzyme (ACE) inhibitors as the drug of choice over angiotensin receptor blockers (ARBs). (LOE=1b)